The current evidence regarding the safety and immunogenicity of human papillomavirus (HPV) vaccinations for people living with HIV (PLWH) is unclear. We searched PubMed, Embase, Cochrane Library and Web of Science databases from inception to 23 November 2018. The pooled proportion, relative risk (RR) and the standardized mean difference (SMD) with 95% confidence intervals (CIs) were calculated. Twenty-four studies consisting of 7507 participants were identified. The pooled proportion of adverse events in HIV-infected vaccinees was 60% and the antibody seroconversion rates in HPV-6, -11, -16, -18 subtypes were all above 90%. When compared with the placebo groups, the risk of adverse events was not different except for the injection site reactions (RR: 2.63, 95% CI: 1.72–4.01, p < 0.001), and the level of CD4 was relatively lower (SMD: −0.17, 95% CI: −0.29 to −0.04, p = 0.01) in the HIV-positive vaccinees groups. When compared with HIV-negative vaccinees, the risk of adverse events was not different, but the pooled RR and SMD indicated that antibody seroconversion and geometric mean titer for HPV-18 in HIV-positive groups was lower (RR: 0.91, 95% CI: 0.87–0.95, p < 0.001; SMD: −0.43, 95% CI: −0.62 to −0.24, p < 0.001). The study proves that HPV vaccine is safe and efficacious for PLWH and has important implications for international guidelines and strategies for HPV vaccination.
CapraGNyitrayAGLuB, et al.
Analysis of persistence of human papillomavirus infection in men evaluated by sampling multiple genital sites. Eur Rev Med Pharmacol Sci2015;
19: 4153–4163.
2.
SmithJSMelendyARanaRK, et al.
Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health2008;
43: S5–25, S25 e21–41.
3.
DalingJRMadeleineMMSchwartzSM, et al.
A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol2002;
84: 263–270.
4.
SmithJSGilbertPAMelendyA, et al.
Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health2011;
48: 540–552.
5.
SyrjanenSTermineNCapraG, et al.
Oral HPV infection: current strategies for prevention and therapy. Curr Pharm Des2012;
18: 5452–5469.
6.
KirnbauerRSchellenbacherCShafti-KeramatS, et al.
HPV infections of the oral and genital mucosa. Possibilities for primary prevention. Hautarzt2009;
60: 878–880.
7.
World Health Organization.
Electronic address swi. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine2017;
35: 5753–5755.
8.
CapraGGiovannelliLMatrangaD, et al.
Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: a referral hospital-based study in Sicily. Hum Vaccin Immunother2017;
13: 1839–1843.
9.
RiethmullerDJacquardACLacau St GuilyJ, et al.
Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health2015;
15: 453–405.
10.
GlickSNFengQPopovV, et al.
High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. J Infect Dis2014;
209: 369–376.
11.
GrulichAEvan LeeuwenMTFalsterMO, et al.
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet2007;
370: 59–67.
12.
SoeNNOngJJMaX, et al.
Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness. Hum Vaccin Immunother2018;
2018: 1–9.
13.
MadhivananPPierre-VictorDMukherjeeS, et al.
Human papillomavirus vaccination and sexual disinhibition in females: a systematic review. Am J Prevent Med2016;
51: 373–383.
14.
MoherDShamseerLClarkeM, et al.
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev2015;
4: 1.
15.
HigginsJGreenS.Cochrane handbook for systematic reviews of interventions, version 5.1.0.
London:
The Cochrane Collaboration, 2013.
16.
HigginsJPAltmanDGGotzschePC, et al.
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;
343: d5928–10.
17.
SlimKNiniEForestierD, et al.
Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg2003;
73: 712–716.
18.
WellsGASheaBO'ConnellD, et al.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2011, accessed 9 May 2019).
19.
DuvalSTweedieR.Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics2000;
56: 455–463.
20.
AndersonJSHoyJHillmanR, et al.
A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr2009;
52: 371–381.
LevinMJMoscickiABSongLY, et al.
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr2010;
55: 197–204.
23.
WilkinTLeeJYLensingSY, et al.
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis2010;
202: 1246–1253.
24.
OldakowskaAMarczynskaMDoboszS, et al.
Evaluation of antibody response to HPV vaccination in HIV infected girls. Przegl Epidemiol2012;
66: 651–655.
25.
DennyLHendricksBGordonC, et al.
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine2013;
31: 5745–5753.
26.
KahnJAXuJKapogiannisBG, et al.
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis2013;
57: 735–744.
27.
GiacometVPenaginiFTrabattoniD, et al.
Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine2014;
32: 5657–5661.
28.
KojicEMKangMCespedesMS, et al.
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis2014;
59: 127–135.
29.
ToftLStorgaardMMuellerM, et al.
Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis2014;
209: 1165–1173.
30.
FaustHToftLSehrP, et al.
Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine2016;
34: 1559–1565.
31.
FontesAAndreoliMAVillaLL, et al.
High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in Sao Paulo, Brazil. Papillomavirus Res2016;
2: 17–20.
32.
MoneyDMMosesEBlitzS, et al.
HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine2016;
34: 4799–4806.
Hidalgo-TenorioCRamírez-TaboadaJGil-AnguitaC, et al.
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). AIDS Res Ther2017;
14: 34.
35.
KahnJAXuJKapogiannisBG, et al.
Antibody responses to quadrivalent HPV vaccination in HIV-infected young women as measured by total IgG and competitive luminex immunoassay. J Acquir Immune Defic Syndr2017;
75: 241–245.
36.
LevinMJHuangSMoscickiA-B, et al.
Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: effect of a fourth dose of vaccine. Vaccine2017;
35: 1712–1720.
37.
BrophyJBitnunAAlimentiA, et al.
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV. Pediat Infect Dis J2018;
37: 595–597.
38.
CespedesMSKangMKojicEM, et al.
Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res2018;
6: 15–21.
39.
EllsworthGBLensingSYOgilvieCB, et al.
A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus Res2018;
6: 11–14.
40.
MugoNREckertLMagaretAS, et al.
Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: month 7 and 12 post vaccine immunogenicity and correlation with immune status. Vaccine2018;
36:7025–7032.
41.
WeinbergAHuangSMoscickiAB, et al.
Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS2018;
32: 851–859.
42.
WilkinTJChenHCespedesMS, et al.
A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis2018;
67: 1339–1346.
43.
Zurek Munk-MadsenMToftLKubeT, et al.
Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Hum Vaccin Immunother2018;
14: 909–916.
44.
JouraEAGiulianoARIversenOE, et al.
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med2015;
372: 711–723.
45.
YangDYBrackenK.Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician2016;
62: 399–402.
46.
GarlandSMKjaerSKMunozN, et al.
Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis2016;
63: 519–527.
47.
GianniniSLHanonEMorisP, et al.
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine2006;
24: 5937–5949.
48.
LuxembourgABrownDBouchardC, et al.
Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother2015;
11: 1313–1322.
49.
NaudPSRoteli-MartinsCMDe CarvalhoNS, et al.
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother2014;
10: 2147–2162.
50.
NygardMSaahAMunkC, et al.
Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol2015;
22: 943–948.
51.
PetryKUBollaertsKBonanniP, et al.
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. Hum Vaccin Immunother2018;
14: 1800–1806.
52.
SimmsKTSteinbergJCaruanaM, et al.
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol2019;
20: 394–407.
53.
HarperDMDeMarsLR.HPV vaccines – a review of the first decade. Gynecol Oncol2017;
146: 196–204.
54.
OlssonSEVillaLLCostaRL, et al.
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine2007;
25: 4931–4939.
55.
GuevaraACabelloRWoelberL, et al.
Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. Vaccine2017;
35: 5050–5057.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
